IL6R and Autoimmunity: Moreover, increased circulating Treg levels and clinical benefits were observed in patients receiving IL-6R blockade by tocilizumab for management of autoimmune disorders at risk or during manifestation of autoimmunity-mediated renal disease (106, 107, 109).